PHVS
PharvarisDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-20
Current thesis
Composite grade D from latest DB weights. Momentum 58.0 / Value 41.1
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta +0.0.
What can break
Mixed signals. Wait for cleaner trend confirmation.
Momentum
58
Value
41
Sentiment
N/A
Setup hits (3d)
0 · Net Neutral
AI TargetsBase - · Bull - · Bear -
Data freshness
Prices
As of 2026-07-20
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-20 • Model: HYBRID_IC_RP
AI Memo
Unavailable: No memo yet
Investment thesisAs of 2026-07-20
Investment thesis
As of 2026-07-20
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $47.07
Why
Momentum58 · Δ7d +13.2
Value41 · Δ7d +0.0
SentimentN/A · Δ7d -
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Value · See fundamentals
Momentum
58
40% active weight
Current posture
7d trendFlat
Δ7d
+13.2
Δ21d
+2.2
Value
41
60% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
-0.1
Sentiment
N/A
Coverage pending
No current score
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade D. Momentum 58.0 / Value 41.1
Fundamentals (TTM)As of 2026-07-17
Fundamentals (TTM)
As of 2026-07-17
Market Cap
$2.44B
Beta
-2.78
Shares Out
69.86M
P/E (TTM) · Derived
-10.4
P/S (TTM)
-
P/FCF (TTM) · Derived
-12.31
Rev YoY
-
EPS YoY
-21.5%
Gross Margin
-
Op Margin
-
Net Debt
-$341.65M
Current Ratio
11.24
As of 2026-07-20 • Updated nightlySource: Internal modelMethodology